PTC Therapeutics, Inc. Deferred Tax Assets, Operating Loss Carryforwards, State and Local
PTC Therapeutics, Inc. (PTCT) had Deferred Tax Assets, Operating Loss Carryforwards, State and Local of $13.03 million as of 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal · last filed 2026-02-19
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards, State and Local $13.03M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards, State and Local $13.32M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards, State and Local $18.68M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards, State and Local $10.32M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, State and Local | Deferred Tax Assets, Operating Loss Carryforwards, State and Local as first filed |
|---|---|---|
| 2025-12-31 | $13.03M 10-K · filed 2026-02-19 | |
| 2024-12-31 | $13.32M 10-K · filed 2026-02-19 | |
| 2023-12-31 | $18.68M 10-K · filed 2025-02-27 | |
| 2022-12-31 | $10.32M 10-K · filed 2024-02-29 | |
| 2021-12-31 | $9.16M 10-K · filed 2023-02-21 | |
| 2020-12-31 | $1.43M 10-K · filed 2022-02-22 | |
| 2019-12-31 | $1.36M 10-K · filed 2021-02-25 | |
| 2018-12-31 | $165.00K 10-K · filed 2020-03-02 | |
| 2017-12-31 | $11.88M 10-K · filed 2019-03-01 | |
| 2016-12-31 | $9.67M 10-K · filed 2018-03-06 | |
| 2015-12-31 | $8.85M 10-K · filed 2017-03-16 | |
| 2014-12-31 | $9.19M 10-K · filed 2016-02-29 | |
| 2013-12-31 | $10.46M 10-K · filed 2015-03-02 | $10.46M 10-K · filed 2014-03-06 |
| 2012-12-31 | $7.62M 10-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |